Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–9 of 9 results
Advanced filters: Author: "Tyler Jacks" Clear advanced filters

  • The CRISPR–Cas9 (clustered regularly interspaced short palindromic repeats–CRISPR-associated 9) system provides many avenues for improving how we generate models of cancer. This system has numerous uses, including providing a means to understand the importance of genetic alterations as a tumour evolves, and CRISPR–Cas9 may potentially constitute a therapeutic strategy in the future.

    • Francisco J. Sánchez-Rivera
    • Tyler Jacks
    Reviews
    Nature Reviews Cancer
    Volume: 15, P: 387-393

  • Metastasis accounts for the vast majority of cancer deaths. The potential of using nanoparticles to diagnose and to treat metastatic cancer is highlighted in this Review.

    • Avi Schroeder
    • Daniel A. Heller
    • Daniel G. Anderson
    Reviews
    Nature Reviews Cancer
    Volume: 12, P: 39-50

  • Several recent papers have shown that the miR-34 family of microRNAs is directly involved in mediating the effects of p53, indicating that non-coding RNAs have an important role in tumorigenesis. This Progress article discusses these papers and their implications.

    • Lin He
    • Xingyue He
    • Gregory J. Hannon
    Reviews
    Nature Reviews Cancer
    Volume: 7, P: 819-822

  • Desmosomes are adhesion complexes that are related to adherens junctions, and recent studies using mouse genetic approaches have uncovered a role for desmosomes in tumour suppression.

    • Rachel L. Dusek
    • Laura D. Attardi
    Reviews
    Nature Reviews Cancer
    Volume: 11, P: 317-323

  • The human tumour suppressor LKB1 directly phosphorylates and activates AMPK, a central metabolic sensor. AMPK is a key therapeutic target in patients with diabetes, and the connection between AMPK and several tumour suppressors suggests that therapeutic manipulation of this pathway using established diabetes drugs warrants investigation in patients with cancer.

    • David B. Shackelford
    • Reuben J. Shaw
    Reviews
    Nature Reviews Cancer
    Volume: 9, P: 563-575

  • More than half of all patients with cancer receive radiation therapy, but normal tissue tolerance to radiation often limits the ability to cure tumours with radiation therapy. Here, Moding, Kastan and Kirsch discuss current approaches and possible future directions for combining radiation therapy with targeted therapies to enhance the probability of tumour cure.

    • Everett J. Moding
    • Michael B. Kastan
    • David G. Kirsch
    Reviews
    Nature Reviews Drug Discovery
    Volume: 12, P: 526-542

  • There are many cellular outcomes attributable to p53 activation, but identifying which of these, or which combination of these, is important for tumour suppression has remained challenging. As new roles for p53 emerge, this Opinion dissects the role of p53 in tumour suppression.

    • Kathryn T. Bieging
    • Stephano Spano Mello
    • Laura D. Attardi
    Reviews
    Nature Reviews Cancer
    Volume: 14, P: 359-370